CHENGDU DIKANG PHARMACEUTICAL CO., LTD.

CHENGDU DIKANG PHARMACEUTICAL CO., LTD. is a legitimate registered non-Hong Kong company duly registered under Part 16 of the Companies Ordinance (Cap. 622) of Hong Kong on 1971-08-24 (operating for 55 years). According to the official register of the Hong Kong Companies Registry (CR), the entity holds an active statutory status of [Live / In Operation] (Statutory records last verified: October 2026).

The statutory primary identifiers for CHENGDU DIKANG PHARMACEUTICAL CO., LTD. are: 1. Business Registration Number (BRN / Unique Business Identifier UBI): [70043585] (effective from 27 December 2023, this 8-digit number issued under Cap. 310 serves as the unified cross-departmental corporate identifier); 2. Company Registration Number (CRN): [F0024944] (incorporation archive number issued under Cap. 622). Together, these dual keys uniquely lock the entity in international banking KYC and cross-border contracts.

Under Part 16 of the Companies Ordinance (Cap. 622), CHENGDU DIKANG PHARMACEUTICAL CO., LTD. is a Registered Non-Hong Kong Company incorporated outside Hong Kong. In Hong Kong, its registered corporate governance records comprise: 1. Latest Annual Return (Form NN3, Section 788) for current directors and company secretary; 2. Form NN7 for interim alterations of directors or secretaries; 3. Form NN8 for Authorized Representatives registered in Hong Kong (Section 786) authorized to accept legal process and notices on its behalf; and 4. Initial Application Form NN1. Because the entity was incorporated outside Hong Kong, its overall equity share capital and complete register of members are maintained under the company laws of its home jurisdiction of incorporation (and listing disclosures if publicly listed), rather than local Form NAR1 or NSC1 filings.

Yes. Official filing registers of the Hong Kong Companies Registry confirm that CHENGDU DIKANG PHARMACEUTICAL CO., LTD. has statutory filings on official record. Pursuant to Part 16 (Section 788) of the Companies Ordinance (Cap. 622), registered non-Hong Kong companies must deliver an Annual Return (Form NN3) to the Registrar of Companies within 42 days after each registration anniversary. Available verified original dossiers include: latest Annual Return of Non-Hong Kong Company (Form NN3 - detailing principal place of business in Hong Kong and authorised representatives), Application for Registration (Form NN1), Constitutive Documents, and Change of Secretary/Director/Authorised Representative notices (Form NN7 / NN8C), all carrying official ICRIS barcode verification.

According to multi-dimensional checks across Hong Kong statutory authorities: 1. Regulatory Licences: Cross-referenced across Hong Kong statutory regulatory registers (including HKMA, SFC, Companies Registry TCSP, Customs MSO/DPMS, and Insurance Authority IA), this entity holds no special statutory financial licence, operating as a general commercial corporation; 2. Judicial Screening (Litigation & Winding-Up): cross-referenced with the Hong Kong Judiciary public writs database and Official Receiver's Office (ORO) registers; no public civil action writs (HCA/DCCJ) or compulsory winding-up petitions (HCCW under Cap. 32) were found on current index records.

When executing commercial contracts or conducting cross-border due diligence on CHENGDU DIKANG PHARMACEUTICAL CO., LTD. (CRN: F0024944 / 8-digit BRN: 70043585), compliance verification covers four core pillars: 1. Statutory registration & dual identifiers: verify active registration under Cap. 622 Part 16 and Inland Revenue Department Business Registration (Cap. 310); 2. Hong Kong signing authority: inspect registered directors and Hong Kong Authorized Representatives appointed under Section 786 via latest Form NN3, Form NN7, and Form NN8 (non-Hong Kong companies execute documents through registered authorized representatives or directors under their home constitution, rather than local NAR1/ND2A forms); 3. Place of incorporation verification: inspect constituent documents and public disclosures from its home jurisdiction or stock exchange; and 4. Judicial litigation screening: search High Court civil actions (HCA) and winding-up petitions (HCCW).